Clinical trial of adjuvant peptide vaccine therapy for oral cancer研究代表者

我们使用这些肽的癌症疫苗治疗对口腔癌具有良好的耐受性。术后局部复发转移5例（腹膜播散1例，肺转移1例，颈淋巴转移1例，局部复发2例，1例）。然而，没有腹膜传播的转移灶被切除，所有病例都继续使用这些肽进行疫苗接种治疗。在所有病例中，治疗后未发现复发和/或转移。在HLA-24（+）组中，ELISPOT检测显示接种后URLC10-、CDCA1-和koc1特异性CTL应答分别为88.2%、82.4%和52.9%。表现出URLC10和CDCA1特异性ctl反应的患者分别表现出较好的临床反应。结论：使用这些肽接种V具有良好的耐受性，并且观察到可测量的免疫反应和抗肿瘤效果。该疫苗引起的免疫应答可使头颈癌患者预后较好

Our cancer vaccination therapy using these peptides was welltolerated for oral cancer . 5 patients showed a postoperative local recurrence and metastasis(peritoneal dissemination;1 case, lung metastasis;1 case , cervical lymph node metastasis; 2cases and local recurrence; 1case). However , metastatic foci without peritoneal disseminationwere removed and all cases are continued vaccination therapy using these peptides. In all ofcases, recurrence and/or metastasis are not recognized after treatment.In the HLA-24(+) group, ELISPOT assay indicated that the URLC10-, CDCA1-, andKOC1-specific CTL responses were observed after the vaccination in 88.2%, 82.4%, and 52.9%,of the HLA-24(+) group, respectively. The patients showing URLC10 and CDCA1 specificCTL responses revealed the better clinical response, respectively. Conclusions: V accination using these peptides was well tolerated, and measurable immuneresponses and antitumor efficacy are observed. The immune response induced by thisvaccination can make their prognosis better for head and neck cancer patients